SHAREHOLDER NOTICE: Goldberg Law PC Announces Securities Class Action Lawsuit against Esperion Therapeutics, Inc. & Encourage...
January 19 2016 - 2:58PM
Business Wire
Goldberg Law PC (www.Goldberglawpc.com) announces that a class
action lawsuit has been filed against Esperion Therapeutics, Inc.
(“Esperion” or the “Company”) (Nasdaq: ESPR). Investors who
purchased or otherwise acquired shares between August 18, 2015 and
September 28, 2015, (the “Class Period”), are encouraged to contact
the firm in advance of the March 14, 2016, lead plaintiff motion
deadline.
If you are a shareholder who suffered a loss during the Class
Period, we advise you to contact Michael Goldberg or Brian Schall,
of Goldberg Law PC, 13650 Marina Pointe Dr. Suite 1404, Marina Del
Rey, CA 90292, at 800-977-7401, to discuss your rights without cost
to you. You can also reach us through the firm’s website at
http://www.Goldberglawpc.com, or by email at
info@goldberglawpc.com.
The class in this case has not yet been certified, and until
certification occurs, you are not represented by an attorney. If
you choose to take no action, you can remain an absent class
member.
According to the complaint, the Company had no clear path to
approval for ETC-1002, the Company’s lead product candidate
designed to lower LDL-cholesterol levels. In addition, the FDA had
encouraged the Company to initiate a cardiovascular outcomes trial
(“CVOT”) and that completion of a CVOT could be necessary prior to
approval of ETC-1002.
Goldberg Law PC represents shareholders around the world and
specializes in securities class actions and shareholder rights
litigation.
This press release may be considered Attorney Advertising in
some jurisdictions under the applicable law and ethical rules.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20160119006723/en/
Goldberg Law PC, Los AngelesMichael Goldberg, Esq.,
800-977-7401Brian Schall, Esq.,
800-977-7401info@goldberglawpc.com
Esperion Therapeutics (NASDAQ:ESPR)
Historical Stock Chart
From Jun 2024 to Jul 2024
Esperion Therapeutics (NASDAQ:ESPR)
Historical Stock Chart
From Jul 2023 to Jul 2024